Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RAPT Therapeutics Q3 EPS $(0.63), Same YoY

RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.63) per share. This is unchanged from the same period last year.

byBenzinga Newsdesk

November 10, 2022

1 minute read

RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.63) per share. This is unchanged from the same period last year.

Citigroup Maintains Neutral on Teladoc Health, Lowers Price Target to $36

By Benzinga Newsdesk

Today, 11:44 AM

Citigroup analyst Daniel Grosslight maintains Teladoc Health (NYSE:TDOC) with a Neutral and lowers the price target from $38 to $36.

TDOC

JMP Securities Maintains Market Outperform on Asana, Lowers Price Target to $21

By Benzinga Newsdesk

Today, 11:44 AM

JMP Securities analyst Patrick Walravens maintains Asana (NYSE:ASAN) with a Market Outperform and lowers the price target from $28 to $21.

ASAN

BitNile Holdings Contemplates Exchange Offer To Acquire Shares Of Its Common Stock

By Benzinga Newsdesk

Today, 11:44 AM

BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), today announced that the Company is considering undertaking an exchange offer (the

NILE

DA Davidson Upgrades PaySign to Buy

By Benzinga Newsdesk

Today, 11:44 AM

DA Davidson analyst Peter Heckmann upgrades PaySign (NASDAQ:PAYS) from Neutral to Buy.

PAYS

RAPT Therapeutics Q3 EPS $(0.63), Same YoY

Related Posts

Citigroup Maintains Neutral on Teladoc Health, Lowers Price Target to $36

JMP Securities Maintains Market Outperform on Asana, Lowers Price Target to $21

BitNile Holdings Contemplates Exchange Offer To Acquire Shares Of Its Common Stock

DA Davidson Upgrades PaySign to Buy